Literature DB >> 9305514

Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

S H Ferris1, U Lucca, R Mohs, B Dubois, K Wesnes, H Erzigkeit, D Geldmacher, N Bodick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9305514

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


× No keyword cloud information.
  10 in total

1.  Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial.

Authors:  P J G H Kamphuis; F R J Verhey; M G M Olde Rikkert; J W R Twisk; S H N Swinkels; P Scheltens
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

2.  Computerized neurocognitive testing and its potential for modern psychiatry.

Authors:  C Thomas Gualtieri
Journal:  Psychiatry (Edgmont)       Date:  2004-09

Review 3.  A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact.

Authors:  M D Walker; S S Salek; A J Bayer
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

Review 4.  Rivastigmine. A review of its use in Alzheimer's disease.

Authors:  C M Spencer; S Noble
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

5.  The value of assessing cognitive function in drug development.

Authors:  K A Wesnes
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

6.  The evaluation of cognitive function in the dementias: methodological and regulatory considerations.

Authors:  Keith A Wesnes; John E Harrison
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

Review 7.  Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity.

Authors:  Keith A Wesnes
Journal:  Alzheimers Res Ther       Date:  2014-08-29       Impact factor: 6.982

8.  Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research.

Authors:  Craig W Ritchie; Graciela Muniz Terrera; Terence J Quinn
Journal:  Alzheimers Res Ther       Date:  2015-03-18       Impact factor: 6.982

9.  Which Cognitive Domains are Improved by Treatment with Vortioxetine?

Authors:  John E Harrison; Søren Lophaven; Christina K Olsen
Journal:  Int J Neuropsychopharmacol       Date:  2016-05-26       Impact factor: 5.176

10.  Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.

Authors:  John E Harrison
Journal:  Alzheimers Res Ther       Date:  2018-06-29       Impact factor: 6.982
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.